Nightstar Therapeutics

Description

⋅ Nov 22, 2017 4:10 AM

11/20/2017
800M market cap. 23 employees. UK.
69M in cash. Burning 10M/yr
a gene therapy for the treatment of CHM. We expect to begin Phase 3 clinical development of NSR-REP1 in the first half of 2018. Phase II data due?

Beyond Technical Analysis

Comments

fredtahmasian

⋅ Nov 22, 2017 4:11 AM

Study.